Eterna Therapeutics (ERNA) Institutional Ownership $1.04 -0.05 (-4.59%) (As of 11/1/2024 ET) Add Compare Share Share Ownership Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends Institutional Ownership Changes (13F Filings) for Eterna Therapeutics (NASDAQ:ERNA)CurrentInstitutional OwnershipPercentage70.55%Number ofInstitutional Buyers(last 12 months)4TotalInstitutional Inflows(last 12 months)$1.07MNumber ofInstitutional Sellers(last 12 months)0 Get ERNA Insider Trade Alerts Want to know when executives and insiders are buying or selling Eterna Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address Skip Chart & View Institutional Buying and Selling Data ERNA Institutional Buying and Selling by Quarter Ad Crypto 101 MediaCrypto Crash Ahead? (27 Experts Weigh In)Your Portfolio Could Be at RISK Emergency summit reveals crypto could save you!Click here to reserve your spot at the emergency crypto summit now. Eterna Therapeutics Major Shareholders & Ownership History Export to ExcelReporting DateMajor Shareholder NameShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails5/3/2024 Avidian Wealth Solutions LLC14,798$36K0.0%N/A0.274% 5/2/2024 Sippican Capital Advisors72,800$175K0.1%+34.7%1.346% 2/13/2024 Lake Street Advisors Group LLC520,996$933K0.1%N/A9.630% 1/30/2024 Sippican Capital Advisors54,050$97K0.1%+92.3%0.999% 1/1/2024Vanguard Group Inc.24,898$54K0.0%+30.6%0.460% 10/24/2023 Sippican Capital Advisors28,100$61K0.1%+30.1%0.519% 2/1/2023Cypress Point Wealth Management LLC94,375$304K0.5%N/A3.210% 1/31/2023 Naviter Wealth LLC79,621$387K0.1%N/A2.708% (Data available from 1/1/2016 forward) ERNA Institutional Ownership - Frequently Asked Questions Who are the largest shareholders of ERNA shares? During the previous two years, the following institutional investors and hedge funds held shares of Eterna Therapeutics shares: Lake Street Advisors Group LLC ($933K), Naviter Wealth LLC ($387K), Cypress Point Wealth Management LLC ($304K), Sippican Capital Advisors ($175K), and Vanguard Group Inc. ($54K), Avidian Wealth Solutions LLC ($36K).Learn more on ERNA's institutional investors. What percentage of Eterna Therapeutics stock is owned by institutional investors? 70.55% of Eterna Therapeutics stock is owned by institutional investors. Learn more on ERNA's institutional investor holdings. Which institutional investors have been buying Eterna Therapeutics stock? The following institutional investors have purchased Eterna Therapeutics stock in the last 24 months: Lake Street Advisors Group LLC ($521.00K), Cypress Point Wealth Management LLC ($94.38K), Naviter Wealth LLC ($79.62K), Sippican Capital Advisors ($51.20K), Avidian Wealth Solutions LLC ($14.80K), and Vanguard Group Inc. ($5.83K). How much institutional buying is happening at Eterna Therapeutics? Institutional investors have bought a total of 766,819 shares in the last 24 months. This purchase volume represents approximately $1.65M in transactions. Related Companies RNXT Major Shareholders CYTH Major Shareholders APRE Major Shareholders NNVC Major Shareholders GLMD Major Shareholders INDP Major Shareholders PMN Major Shareholders ITRM Major Shareholders FNCH Major Shareholders MIRA Major Shareholders This page (NASDAQ:ERNA) was last updated on 11/2/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredEx WH Advisor Who Predicted Biden Leaving Race Makes Startling New PredictionFormer advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's...Chaikin Analytics | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredThe centerpiece of Trump’s crypto’s masterplan …Donald Trump wants to be America’s first crypto president. He was the keynote speaker at the recent Bitcoin...Weiss Ratings | SponsoredBlackrock’s Sending THIS Crypto Higher on PurposeIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredThe Final FrontierAnd a lot of powerful investors would rather this exposé never saw the light of day. I suspect they’ll attempt...Porter & Company | SponsoredWall St. Legend: Millions of Americans About to Fall Out of the 1%Wall Street insider reveals the financial tidal wave about to knock millions of Americans out of the One Perce...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Eterna Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Eterna Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
